PCVX Stock — Vaxcyte Inc.: Cash, EV, Pipeline

Share price

$58.13

Market cap

$8,650.1M

Cash

$1,486.8M

Enterprise value

$7,163.3M

Balance sheet

Cash	$1,486.8M
Debt	$0.0M
Net cash	$1,486.8M
Enterprise value	$7,163.3M
Basic shares	144.8M shares
Fully diluted shares	177.3M shares
Fully diluted market cap	$10,309.0M
Cash per share	$10.27

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading PCVX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 12 - Mar 26	PCV20	Phase 3	Pneumococcal Vaccines	H1 2027
Apr 12 - May 24	PCV20	Phase 3	Pneumococcal Vaccines	H1 2027
Jan 12 - Feb 23	0.5 mL of the low dose VAX-31	Phase 2	Pneumococcal Vaccines	—
Jan 12 - Feb 23	VAX-A1 Low	Phase 1	Group A Streptococcal Infection	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

VAX-31

Phase 3 · Active Modality: pneumococcal conjugate vaccine

Target S. pneumoniae (31 serotypes)

Partnerships Lonza (preferred, non-exclusive manufacturing supplier; commercial suite handed over August 2026)

Indications

invasive pneumococcal disease and pneumonia in adults 50 and older (OPUS-1/OPUS-2/OPUS-3) (Stage not disclosed)
invasive pneumococcal disease in infants (Phase 2) (Stage not disclosed)

Catalysts

— None
— None
— None
— None

Status note 31-valent, broad-spectrum, carrier-sparing PCV. FDA Breakthrough Therapy designation for prevention of IPD in adults (expanded August 2025 to include pneumonia). Adult OPUS-1/2/3 fully enrolled (6,191 adults dosed). Pending infant Phase 2 readout, Phase 3 infant program planned with Optimized Dose of VAX-24 or VAX-31.

VAX-24

Phase 2 · Active Modality: pneumococcal conjugate vaccine

Target S. pneumoniae (24 serotypes)

Indications

invasive pneumococcal disease in infants (Stage not disclosed)

Status note 24-valent, broad-spectrum, carrier-sparing PCV. Infant Phase 2 final data announced November 2025; Phase 3 infant program under consideration alongside VAX-31.

VAX-A1

Phase 1 · Active Modality: conjugate vaccine

Target polyrhamnose (Group A Strep)

Indications

Group A Streptococcus disease (Stage not disclosed)

Catalysts

— None

Status note Novel conjugate vaccine for Group A Strep; preclinical proof of concept published December 2020. Phase 1 adult study initiated June 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	31 valent pneumococcal conjugate vaccine
Lead indication	Pneumococcal Vaccines
Lead phase	Phase 3
Active trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07284654	Phase 3	Active, not recruiting	Sponsor	PCVX	—	Pneumococcal Vaccines	H1 2027
NCT07365826	Phase 3	Active, not recruiting	Sponsor	PCVX	—	Pneumococcal Vaccines	H1 2027
NCT07425392	Phase 3	Active, not recruiting	Sponsor	PCVX	—	Pneumococcal Vaccines	H1 2027
NCT06720038	Phase 2	Active, not recruiting	Sponsor	PCVX	—	Pneumococcal Vaccines	—
NCT07616934	Phase 1	Recruiting	Sponsor	PCVX	—	Group A Streptococcal Infection	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Vaxcyte, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	388,682	-40,000	3.70%	2026-08-14
ADAR1 Capital Management	146,034	-113,103	0.40%	2026-08-14
Logos Global Management	0	-300,000	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

PCVX — Vaxcyte Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders